U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449936) titled 'COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME' on Feb. 27.
Brief Summary: This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Diabetic Macular Edema
DME
Diabetic Macular Edema (DME)
Intervention:
DRUG: EYP-1901
Intravitreal Injection
DRUG: Aflibercept (2.0 mg)
Intravitreal Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: EyePoint Pharmaceuticals, Inc.
Published by HT Digital Content Services with permission from Health Daily Dige...